Program
mirvetuximab soravtansine
Also written as “Mirvetuximab Soravtansine”, “Mirvetuximab soravtansine” and “TAK-853”.
Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Neoplasms, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 115 open or running | phase 3since Dec 10, 2015 | May 30, 2012 | Nov 2026phase 2 · NCT05456685 |
| AGO Research | 11 open or running | phase 2since Feb 10, 2020 | Feb 10, 2020 | none ahead |
| Huadong Medicine | 10 open or running | phase 3since Nov 14, 2022 | Nov 14, 2022 | none ahead |
| Pheast Therapeutics | 11 open or running | phase 1since Feb 10, 2025 | Feb 10, 2025 | Apr 2029phase 1 · NCT06840886 |
| Takeda | 11 open or running | phase 2since Apr 26, 2024 | Apr 26, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since May 30, 2012.
- Nov 6, 2015Phase 2 study in Carcinoma, Ovarian EpithelialAbbVie · NCT02606305 · 264 enrolled · United States, Belgium, Canada and more
- Dec 10, 2015Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
- Dec 17, 2019Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT04209855 · 453 enrolled · United States, Australia, Belgium and more
- Feb 10, 2020AGO Research’s first study: phase 2 study in Recurrent Epithelial Ovarian, Fallopian or Peritoneal CarcinomaNew to AGO ResearchAGO Research · NCT04274426 · 136 enrolled · Germany
- Feb 27, 2020Phase 3 study in Carcinoma, Ovarian EpithelialAbbVie · NCT04296890 · 106 enrolled · United States, Australia, Belgium and more
- Aug 24, 2021Phase 2 study in Ovarian NeoplasmsAbbVie · NCT05041257 · 79 enrolled · United States, Australia, Belgium and more
- Jun 29, 2022Phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT05456685 · 125 enrolled · United States, Belgium, Canada and more
- Jun 30, 2022Phase 3 study in Ovarian NeoplasmsAbbVie · NCT05445778 · 520 enrolled · United States, Argentina, Australia and more
- Nov 14, 2022Huadong Medicine’s first study: phase 3 study in Carcinoma, Ovarian EpithelialNew to Huadong MedicineHuadong Medicine · NCT05622890 · 35 enrolled · China
- Apr 26, 2024Takeda’s first study: phase 2 study in Ovarian NeoplasmsNew to TakedaTakeda · NCT06390995 · 28 enrolled · Japan
- Nov 8, 2024Phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT06682988 · 110 planned · United States, Australia, Belgium and more
- Feb 10, 2025Pheast Therapeutics’ first study: phase 1 study in Ovarian NeoplasmsNew to Pheast TherapeuticsPheast Therapeutics · NCT06840886 · 426 planned · United States
- Mar 20, 2025Phase 2 study in Carcinoma, Ovarian EpithelialAbbVie · NCT06890338 · 140 planned · United States
- Jul 2, 2025Phase 2 study in Ovarian NeoplasmsAbbVie · NCT07059845 · 400 planned · United States, Australia, Belgium and more
Ahead
- Nov 2026Primary completion: phase 2 study in Fallopian Tube NeoplasmsAbbVie · NCT05456685
- Apr 2027Primary completion: phase 3 study in Ovarian NeoplasmsAbbVie · NCT05445778
- Jan 2029Primary completion: phase 2 study in Ovarian NeoplasmsAbbVie · NCT07059845
- Apr 2029Primary completion: phase 1 study in Ovarian NeoplasmsPheast Therapeutics · NCT06840886
TargetBeta
“An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) ”NCIt, by rule
“Folate receptor alpha binding agent”ChEMBL 37, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07059845Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | AbbVie | Jan 2029 | 400 |
| NCT06890338Carcinoma, Ovarian Epithelial · United States | 2 | Recruiting | AbbVie | Feb 2030 | 140 |
| NCT06840886Ovarian Neoplasms · United States | 1 | Recruiting | Pheast Therapeutics | Apr 2029 | 426 |
| NCT06682988Fallopian Tube Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | AbbVie | Jul 2026 | 110 |
| NCT06390995Ovarian Neoplasms · Japan | 2 | Active, not recruiting | Takeda | Apr 16, 2025 | 28 |
| NCT05622890Carcinoma, Ovarian Epithelial · China | 3 | UNKNOWN | Huadong Medicine | Apr 30, 2023 | 35 |
| NCT05445778Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AbbVie | Apr 2027 | 520 |
| NCT05456685Fallopian Tube Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | AbbVie | Nov 2026 | 125 |
| NCT05041257Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Completed | AbbVie | Dec 12, 2024 | 79 |
| NCT04296890Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Nov 16, 2021 | 106 |
| NCT04274426Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma · Germany | 2 | Active, not recruiting | AGO Research | Dec 3, 2025 | 136 |
| NCT04209855Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more | 3 | Completed | AbbVie | Mar 6, 2023 | 453 |
| NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more | 3 | Completed | AbbVie | Jan 2019 | 366 |
| NCT02606305Carcinoma, Ovarian Epithelial · United States, Belgium, Canada and more | 2 | Completed | AbbVie | Mar 12, 2021 | 264 |
| NCT01609556Neoplasms · United States, Canada | 1 | Completed | AbbVie | Mar 19, 2018 | 206 |
How it is read
Names in the registry
- “Mirvetuximab Soravtansine”, 8 entries
- “Mirvetuximab soravtansine”, 5 entries
- “TAK-853”, 1 entry
- “Mirvetuximab soravtansine plus Bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 6 studies
- Ovarian Neoplasms, 5 studies
- Fallopian Tube Neoplasms, 2 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.